Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

A pluripotent road to immunoengineering

Nature Reviews Bioengineering volume 1, pages 541–542 (2023)Cite this article

Subjects

Adoptive immunotherapy, particularly chimeric antigen receptor (CAR)-T cells, has had considerable success in treating haematological malignancies. However, the variability, time commitment and cost of engineering cells limit their application. Human pluripotent stem (hPS) cells could provide an off-the-shelf, cheaper and scalable solution.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Illustration of adoptive CAR-T cell therapy.

References

  1. Aghajanian, H., Rurik, J. G. & Epstein, J. A. CAR-based therapies: opportunities for immuno-medicine beyond cancer. Nat. Metab. 4, 163–169 (2022).

    Article  Google Scholar 

  2. Hang, S., Wang, N. & Sugimura, R. T, NK, then macrophages: recent advances and challenges in adaptive immunotherapy from human pluripotent stem cells. Differentiation 130, 51–57 (2023).

    Article  Google Scholar 

  3. Chang, Y. et al. Engineering chimeric antigen receptor neutrophils from human pluripotent stem cells for targeted cancer immunotherapy. Cell Rep. 40, 111128 (2022).

    Article  Google Scholar 

  4. Bachiller, M. et al. NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness. J. Immunother. Cancer 9, e002866 (2021).

    Article  Google Scholar 

  5. Ueda, T. et al. Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells. Nat. Biomed. Eng. 7, 24–37 (2022).

    Article  Google Scholar 

  6. Li, Y.-R. et al. Development of allogeneic HSC-engineered iNKT Cells for off-the-shelf cancer immunotherapy. Cell Rep. Med. 2, 100449 (2021).

    Article  Google Scholar 

  7. Zeleniak, A. et al. De novo construction of T cell compartment in humanized mice engrafted with iPSC-derived thymus organoids. Nat. Methods 19, 1306–1319 (2022).

    Article  Google Scholar 

  8. Lei, Y. & Schaffer, D. V. A fully defined and scalable 3D culture system for human pluripotent stem cell expansion and differentiation. Proc. Natl Acad. Sci. 110, E5039–E5048 (2013).

    Article  Google Scholar 

  9. Taylor, C. J., Peacock, S., Chaudhry, A. N., Bradley, J. A. & Bolton, E. M. Generating an iPSC bank for HLA-matched tissue transplantation based on known donor and recipient HLA types. Cell Stem Cell 11, 147–152 (2012).

    Article  Google Scholar 

  10. Wang, X. et al. A nanofibrous encapsulation device for safe delivery of insulin-producing cells to treat type 1 diabetes. Sci. Transl. Med. 13, eabb4601 (2021).

    Article  Google Scholar 

Download references

Acknowledgements

We thank G. Jin, J. D. Harris and other members of the Bao laboratory for their critical reading of the manuscript. We acknowledge partial funding of this work from the National Cancer Institute (R37CA265926 to X.B.), National Institute of General Medical Sciences (R35GM119787 to Q.D.), and National Science Foundation (2143064 to X.B.). The authors also gratefully acknowledge support from the Purdue Institute for Cancer Research, P30CA023168, Purdue Institute for Integrative Neuroscience (PIIN) and Bindley Biosciences Center, and the Walther Cancer Foundation.

Author information

Authors and Affiliations

  1. Davidson School of Chemical Engineering, Purdue University, West Lafayette, IN, USA

    Yun Chang & Xiaoping Bao

  2. Purdue University Institute for Cancer Research, Purdue University, West Lafayette, IN, USA

    Yun Chang, Qing Deng & Xiaoping Bao

  3. Department of Biological Sciences, Purdue University, West Lafayette, IN, USA

    Qing Deng

Authors
  1. Yun Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qing Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiaoping Bao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xiaoping Bao.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chang, Y., Deng, Q. & Bao, X. A pluripotent road to immunoengineering. Nat Rev Bioeng 1, 541–542 (2023). https://doi.org/10.1038/s44222-023-00056-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s44222-023-00056-2

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research